Key result
Tachyarrhythmias are common in cancer patients due to the malignancy itself, aggressive anticancer treatments, and underlying cardiac conditions, requiring close cardiac monitoring and collaboration between oncologists and cardiologists.
Tachyarrhythmias are common in cancer patients due to the disease, treatments, and underlying conditions, requiring close collaboration between oncologists and cardiologists for early diagnosis and management.
May prompt closer cardio-oncology collaboration; leaves open prospective trials to define monitoring protocols.
Arrhythmia is often detected in cancer patient, from single ventricular premature contractions to sustained ventricular tachycardia, life threatening ventricular fibrillation and sudden cardiac death. Oncology per se, aggressive anticancer treatment, both chemotherapy and radiation and basic cardiac conditions are main causative factors for tachyarrhythmia. In this review we summarize evidence of arrhythmia and emphasize the importance of cardiac monitoring for the early diagnosis, intervention and surveillance of those patients more susceptible to develop proarrhythmia. Oncologists should be fully aware of arrhythmia and the close collaboration between cardiologists and oncologists would result in a better cardiovascular assessment, risk stratification, cardiac monitoring and treatment.
No takes yet. Share an insight, caveat, or question.
Chelombitko et al. (2017) conducted a review in Tachyarrhythmias in cancer patients. Tachyarrhythmias are common in cancer patients due to the malignancy itself, aggressive anticancer treatments, and underlying cardiac conditions, requiring close cardiac monitoring and collaboration between oncologists and cardiologists.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: